comparemela.com


December 22, 2020 healthcare
Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
Regulatory News:
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies for the treatment of a variety of medical conditions including infectious diseases, announced that the company, through its wholly owned subsidiary Aptorum International Limited, has submitted a Clinical Trial Application (CTA) with the Public Health Agency of Canada (Health Canada) to conduct a Phase 1 clinical trial of ALS-4, an orally administered small molecule drug for the treatment of infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA). Pending Health Canada’s approval, the Phase 1 trial is designed to test the safety, tolerability and pharmacokinetics of ALS-4 in healthy volunteers.

Related Keywords

Canada ,Clark Cheng ,Aptorum Group Form ,Aptorum Group Or ,Public Health Agency Of Canada ,Daptorum Group ,Aptorum Group Limited Nasdaq ,Aptorum International ,Health Canada ,Aptorum Group Acticule ,Regulatory News ,Group Limited ,Euronext Paris ,Aptorum International Limited ,Clinical Trial Application ,Public Health Agency ,Methicillin Resistant Staphylococcus ,Pending Health Canada ,Chief Medical Officer ,Executive Director ,Aptorum Group Limited ,Private Securities Litigation Reform Act ,French Autorit ,Des March ,Regulations Delegated ,கனடா ,கிளார்க் செங் ,ஆரோக்கியம் கனடா ,ஒழுங்குமுறை செய்தி ,குழு வரையறுக்கப்பட்டவை ,மருத்துவ சோதனை விண்ணப்பம் ,நிலுவையில் உள்ளது ஆரோக்கியம் கனடா ,தலைமை மருத்துவ அதிகாரி ,நிர்வாகி இயக்குனர் ,ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,தேஸ் அணிவகுப்பு ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.